Cargando…
Development of a novel, high-affinity ssDNA trypsin inhibitor
Inhibitors of serine proteases are not only extremely useful in the basic research but are also applied extensively in clinical settings. Using Systematic Evolution of Ligands by Exponential Enrichment (SELEX) approach we developed a family of novel, single-stranded DNA aptamers capable of specific...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366424/ https://www.ncbi.nlm.nih.gov/pubmed/30727784 http://dx.doi.org/10.1080/14756366.2019.1569648 |
_version_ | 1783393624330862592 |
---|---|
author | Malicki, Stanislaw Ksiazek, Miroslaw Majewski, Pawel Pecak, Aleksandra Mydel, Piotr Grudnik, Przemyslaw Dubin, Grzegorz |
author_facet | Malicki, Stanislaw Ksiazek, Miroslaw Majewski, Pawel Pecak, Aleksandra Mydel, Piotr Grudnik, Przemyslaw Dubin, Grzegorz |
author_sort | Malicki, Stanislaw |
collection | PubMed |
description | Inhibitors of serine proteases are not only extremely useful in the basic research but are also applied extensively in clinical settings. Using Systematic Evolution of Ligands by Exponential Enrichment (SELEX) approach we developed a family of novel, single-stranded DNA aptamers capable of specific trypsin inhibition. Our most potent candidate (T24) and its short version (T59) were thoroughly characterised in terms of efficacy. T24 and T59 efficiently inhibited bovine trypsin with K(i) of 176 nM and 475 nM, respectively. Interestingly, in contrast to the majority of known trypsin inhibitors, the selected aptamers have superior specificity and did not interact with porcine trypsin or any human proteases tested. These included plasmin and thrombin characterised by trypsin-like substrate specificity. Our results demonstrate that SELEX may be successfully employed in the development of potent and specific DNA based protease inhibitors. |
format | Online Article Text |
id | pubmed-6366424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-63664242019-02-15 Development of a novel, high-affinity ssDNA trypsin inhibitor Malicki, Stanislaw Ksiazek, Miroslaw Majewski, Pawel Pecak, Aleksandra Mydel, Piotr Grudnik, Przemyslaw Dubin, Grzegorz J Enzyme Inhib Med Chem Short Communication Inhibitors of serine proteases are not only extremely useful in the basic research but are also applied extensively in clinical settings. Using Systematic Evolution of Ligands by Exponential Enrichment (SELEX) approach we developed a family of novel, single-stranded DNA aptamers capable of specific trypsin inhibition. Our most potent candidate (T24) and its short version (T59) were thoroughly characterised in terms of efficacy. T24 and T59 efficiently inhibited bovine trypsin with K(i) of 176 nM and 475 nM, respectively. Interestingly, in contrast to the majority of known trypsin inhibitors, the selected aptamers have superior specificity and did not interact with porcine trypsin or any human proteases tested. These included plasmin and thrombin characterised by trypsin-like substrate specificity. Our results demonstrate that SELEX may be successfully employed in the development of potent and specific DNA based protease inhibitors. Taylor & Francis 2019-02-06 /pmc/articles/PMC6366424/ /pubmed/30727784 http://dx.doi.org/10.1080/14756366.2019.1569648 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Malicki, Stanislaw Ksiazek, Miroslaw Majewski, Pawel Pecak, Aleksandra Mydel, Piotr Grudnik, Przemyslaw Dubin, Grzegorz Development of a novel, high-affinity ssDNA trypsin inhibitor |
title | Development of a novel, high-affinity ssDNA trypsin inhibitor |
title_full | Development of a novel, high-affinity ssDNA trypsin inhibitor |
title_fullStr | Development of a novel, high-affinity ssDNA trypsin inhibitor |
title_full_unstemmed | Development of a novel, high-affinity ssDNA trypsin inhibitor |
title_short | Development of a novel, high-affinity ssDNA trypsin inhibitor |
title_sort | development of a novel, high-affinity ssdna trypsin inhibitor |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366424/ https://www.ncbi.nlm.nih.gov/pubmed/30727784 http://dx.doi.org/10.1080/14756366.2019.1569648 |
work_keys_str_mv | AT malickistanislaw developmentofanovelhighaffinityssdnatrypsininhibitor AT ksiazekmiroslaw developmentofanovelhighaffinityssdnatrypsininhibitor AT majewskipawel developmentofanovelhighaffinityssdnatrypsininhibitor AT pecakaleksandra developmentofanovelhighaffinityssdnatrypsininhibitor AT mydelpiotr developmentofanovelhighaffinityssdnatrypsininhibitor AT grudnikprzemyslaw developmentofanovelhighaffinityssdnatrypsininhibitor AT dubingrzegorz developmentofanovelhighaffinityssdnatrypsininhibitor |